S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:XCUR

Exicure Stock Forecast, Price & News

$2.31
-0.19 (-7.60 %)
(As of 01/15/2021 04:55 PM ET)
Add
Compare
Today's Range
$2.25
Now: $2.31
$2.54
50-Day Range
$1.77
MA: $1.91
$2.40
52-Week Range
$0.96
Now: $2.31
$3.30
Volume621,705 shs
Average Volume697,161 shs
Market Capitalization$202.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂ-based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.

MarketRank

Overall MarketRank

1.87 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XCUR
CUSIPN/A
CIKN/A
Phone847 673 1700
Employees57

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.30 million
Book Value$0.94 per share

Profitability

Net Income$-26,300,000.00
Net Margins-127.52%

Miscellaneous

Market Cap$202.35 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$2.31
-0.19 (-7.60 %)
(As of 01/15/2021 04:55 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XCUR News and Ratings via Email

Sign-up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exicure (NASDAQ:XCUR) Frequently Asked Questions

How has Exicure's stock been impacted by COVID-19 (Coronavirus)?

Exicure's stock was trading at $1.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XCUR stock has increased by 39.2% and is now trading at $2.31.
View which stocks have been most impacted by COVID-19
.

Is Exicure a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exicure stock.
View analyst ratings for Exicure
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Exicure?

Wall Street analysts have given Exicure a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exicure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exicure's next earnings date?

Exicure is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Exicure
.

How were Exicure's earnings last quarter?

Exicure, Inc. (NASDAQ:XCUR) released its earnings results on Thursday, November, 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.01. The firm earned $2.44 million during the quarter, compared to analyst estimates of $2 million. Exicure had a negative return on equity of 24.26% and a negative net margin of 127.52%.
View Exicure's earnings history
.

What price target have analysts set for XCUR?

5 analysts have issued twelve-month price targets for Exicure's stock. Their forecasts range from $6.00 to $18.00. On average, they expect Exicure's share price to reach $9.60 in the next twelve months. This suggests a possible upside of 315.6% from the stock's current price.
View analysts' price targets for Exicure
or view Wall Street analyst' top-rated stocks.

Who are some of Exicure's key competitors?

Who are Exicure's key executives?

Exicure's management team includes the following people:
  • Dr. Chad A. Mirkin Ph.D., Co-Founder & Director (Age 57, Pay $165k)
  • Dr. David A. Giljohann, CEO, Interim Principal Financial Officer, Corp. Sec. & Director (Age 40, Pay $785.46k)
  • Dr. Matthias G. Schroff Ph.D., Chief Operating Officer (Age 53, Pay $476.31k)
  • Dr. Douglas E. Feltner, Chief Medical Officer

What is Exicure's stock symbol?

Exicure trades on the NASDAQ under the ticker symbol "XCUR."

How do I buy shares of Exicure?

Shares of XCUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exicure's stock price today?

One share of XCUR stock can currently be purchased for approximately $2.31.

How big of a company is Exicure?

Exicure has a market capitalization of $202.35 million and generates $1.30 million in revenue each year. The company earns $-26,300,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Exicure employs 57 workers across the globe.

What is Exicure's official website?

The official website for Exicure is www.exicuretx.com.

How can I contact Exicure?

Exicure's mailing address is 2430 N. Halsted St., Chicago IL, 60614. The company can be reached via phone at 847 673 1700 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.